Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: Data from the 2003 National Survey of Children’s Health. J Invest Dermatol. 2011;131(1):67–73.

Article  CAS  PubMed  Google Scholar 

Langan S, Mulick AR, Rutter CE, Silverwood RJ, Asher I, Garcia-Marcos L, et al. Trends in eczema prevalence in children and adolescents: A Global Asthma Network Phase I Study. Clin Exp Allergy. 2023;53:337–52.

Article  PubMed Central  Google Scholar 

Navarrete-Rodriguez EM, Del-Rio-Navarro BE, Reyes Noriega N, Berber A, Merida Palacio V, Garcia-Almaraz R, et al. Have the prevalence of eczema symptoms increased in the Mexican pediatric population? Prevalence and associated factors according to Global Asthma Network Phase I. World Allergy Organ J. 2022;15(11):100710.

Article  PubMed  PubMed Central  Google Scholar 

Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: Part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–31.

Article  CAS  PubMed  Google Scholar 

Larenas-Linnemann D, Rincon-Perez C, Luna-Pech JA, Macias-Weinmann A, Vidaurri-de la Cruz H, Navarrete-Rodriguez EM, et al. Guidelines on atopic dermatitis for Mexico (GUIDAMEX): Using the ADAPTE methodology. Gac Med Mex. 2023;158(Supplement 2):1–116.

PubMed  Google Scholar 

Panel AAJADG, Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274–312.

Article  Google Scholar 

Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–66.

Article  CAS  PubMed  Google Scholar 

Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020;156(8):863–73.

Article  PubMed  Google Scholar 

Bieber T, Simpson EL, Silverberg JI, Thaci D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101–12.

Article  CAS  PubMed  Google Scholar 

Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023;37(10):2056–66.

Article  CAS  PubMed  Google Scholar 

Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: The JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165–73.

Article  PubMed  Google Scholar 

Cork MJ, McMichael A, Teng J, Valdez H, Rojo R, Chan G, et al. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: An analysis of patient-reported outcomes. J Eur Acad Dermatol Venereol. 2022;36(3):422–33.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104–12.

Article  CAS  PubMed  Google Scholar 

Flohr C, Cork MJ, Ardern-Jones MR, Eichenfield LF, Barbarot S, Feeney C, et al. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: A post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial. J Dermatolog Treat. 2023;34(1):2200866.

Article  PubMed  Google Scholar 

Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: Patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. 2020;33(3):1521–30.

Article  PubMed  Google Scholar 

Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: Results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–55.

Article  CAS  PubMed  Google Scholar 

Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, et al. Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: An extension study of 2 randomized clinical trials. JAMA Dermatol. 2021;157(6):691–9.

Article  PubMed  Google Scholar 

Bieber T, Reich K, Paul C, Tsunemi Y, Augustin M, Lacour JP, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: Results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022;187(3):338–52.

Article  CAS  PubMed  Google Scholar 

Buhl T, Rosmarin D, Serra-Baldrich E, Fernandez-Penas P, Igarashi A, Konstantinou MP, et al. Itch and sleep improvements with baricitinib in patients with atopic dermatitis: A post hoc analysis of 3 phase 3 studies. Dermatol Ther (Heidelb). 2021;11(3):971–82.

Article  PubMed  Google Scholar 

Masuda K, Delozier AM, Kolodsick J, Buchanan A, Pink AE, Sun L, et al. Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: A post hoc analysis from BREEZE-AD7. Eur J Dermatol. 2022;32(2):237–43.

Article  CAS  PubMed  Google Scholar 

de Bruin-Weller MS, Serra-Baldrich E, Barbarot S, Grond S, Schuster C, Petto H, et al. Indirect treatment comparison of baricitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2022;12(6):1481–91.

Article  PubMed  Google Scholar 

Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, Prakash A, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: Results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23–32.

Article  PubMed  Google Scholar 

Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K, et al. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of Upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (rising up): an interim 24-week analysis. JAAD Int. 2022;6:27–36.

Article  PubMed  Google Scholar 

Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K, et al. Safety and efficacy of upadacitinib for atopic dermatitis in japan: 2-year interim results from the phase 3 rising up study. Dermatol Ther (Heidelb). 2023;13(1):221–34.

Article  PubMed  Google Scholar 

Katoh N, Ikeda M, Ohya Y, Murota H, Hu X, Liu J, et al. Safety and efficacy of upadacitinib for atopic dermatitis in Japan: Analysis of the 3-year phase 3 rising up study. Dermatol Ther (Heidelb). 2024;14(1):213–32.

Article  PubMed  Google Scholar 

Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–55.

Article  PubMed  PubMed Central  Google Scholar 

Blauvelt A, Ladizinski B, Prajapati VH, Laquer V, Fischer A, Eisman S, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). J Am Acad Dermatol. 2023;89(3):478–85.

Article  CAS  PubMed  Google Scholar 

Hagino T, Hamada R, Yoshida M, Fujimoto E, Saeki H, Kanda N. Effectiveness and safety of upadacitinib in combination with topical corticosteroids in adolescent patients with moderate-to-severe atopic dermatitis. Clin Cosmet Investig Dermatol. 2023;16:3201–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476–85.

Article  CAS  PubMed  Google Scholar 

Tanaka T, Sasaki T, Ikeda K, Liu J, Tenorio AR, Ohya Y. Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (rising up). World Allergy Organ J. 2022;15(9):100678.